Navigation Links
Data Published in Proceedings of National Academy of Sciences Highlights Potential of Micromet's BiTE Antibody Platform
Date:6/29/2010

against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately inducing a self-destruction process in the tumor cells referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, Boehringer Ingelheim, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.

Safe Harbor

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Calif. , May 4, 2015  Impax Laboratories, ... filled two key executive leadership roles, appointing  Donna M. ... Deborah M. Penza , as Senior Vice President, Chief ... report to Impax,s President and Chief Executive Officer, ... Donna and Deborah have joined the Impax team," said ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
(Date:5/4/2015)... ANGELES , May 4, 2015  CytRx ... and development company specializing in oncology, today announced ... 1b aldoxorubicin combination studies pairing aldoxorubicin with either ... of gemcitabine or ifosfamide with escalating doses of ... and even at the lowest dose level of ...
Breaking Medicine Technology:Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7
... ZymoGenetics,Inc. today announced that interim findings were presented ... B-cell chronic,lymphocytic leukemia (B-CLL) at the American Society ... included intravenous,administration of higher doses than had been ... was well-tolerated and biologically,active at all dose levels ...
... Biotechnology,Inc. (OTCBB: CGRB) today announced that positive interim ... prostate cancer drug candidate,CB7630 (abiraterone acetate) was presented ... Meeting, which is currently,taking place in Chicago, Illinois. ... Saturday, June 2nd, as part of the poster,discussion ...
Cached Medicine Technology:ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 6
(Date:5/4/2015)... May 04, 2015 Now in its ... clinical leaders who have made outstanding contributions to the ... serve, both in acute and post-acute care settings. The ... Post-Acute Provider of the Year, Advanced Practice Clinician of ... Provider of the Year. Recipients are selected by IPC’s ...
(Date:5/4/2015)... Washington, DC (PRWEB) May 04, 2015 ... of Kit Check as a finalist for the EY ... Washington Region. The awards program recognizes entrepreneurs who ... innovation, financial performance and personal commitment to their businesses ... finalist by a panel of independent judges. Award ...
(Date:5/4/2015)... CA (PRWEB) May 04, 2015 ... is now offering a more comfortable and attractive alternative ... restoration of choice for those who have lost teeth. ... can feel insecure or slip at the worst possible ... eats or talks. They can also painfully pinch or ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Ticket Down is ... the Colonial Life Arena in Columbia, South Carolina. ... continuation of his “Out There” tour which originally kicked off ... tour is North America and the legendary performer recently announced ... the Wells Fargo Arena on June 21st, in Charlottesville, VA ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 CCL, a ... offer this unique program to other leadership development consultancies. ... ties between CCL and successful practitioners, expanding our capacity ... the globe,” said John R. Ryan, CCL President and ... the CCL Partner Network , it will schedule ...
Breaking Medicine News(10 mins):Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2
... surpass quarter million dollars, ANAHEIM, Calif., March 18 ... laptop computer carrying cases and,accessories is proud to announce ... in their battle against Breast Cancer. In their fourth,year ... percent of the,retail sales price of each Komen laptop ...
... (OTC Bulletin,Board: NTRZ), a world leader in stabilized rice bran ... step down from,his role as Chief Financial Officer on March ... role of Chief Financial Officer on that date.,Mr. Crow has ... smooth,transition of his responsibilities to Mr. Mueller., Mr. Mueller ...
... Kennedy, BABY MADNESS: MULTIPLES Offers Tips, from Celebrity Moms Kate Gosselin ... ... Baby Bloopers--, SILVER SPRING, Md., March 17 The signs ... basketball and of course, BABY MADNESS! Discovery Health,s second,annual television event ...
... space details Earths land cover with a resolution never before ... Organisation, presented the preliminary version of the map to scientists ... in Rome, Italy. , Earths land cover has been charted ... available to the public upon its completion in July, has ...
... Testing Requirements, VANCOUVER, March 17 /PRNewswire-FirstCall/ - ... the U.S. Food and Drug Administration (FDA),has completed ... (sNDA) for,Aczone(TM) and has removed the glucose-6-phosphate dehydrogenase ... extremely pleased to report the FDA decision to ...
... Care Center at ... Hospital, and Nyack Hospital, HACKENSACK, N.J., March 17 ... anticipated debut in The Kennedy Funding,Invitational for 2008, July 9-13. ... hospital breast care centers. Co-Directors,James Miller, Mitch Klein, and Kevin ...
Cached Medicine News:Health News:Mobile Edge Continues Fight Against Breast Cancer 2Health News:NutraCea Appoints New Chief Financial Officer 2Health News:NutraCea Appoints New Chief Financial Officer 3Health News:Baby Madness is Sweeping the Nation! Forty Sets of Twins and Triplets 'Hit the Court' in Discovery Health's BABY MADNESS: MULTIPLES 2Health News:New portrait of Earth shows land cover as never before 2Health News:QLT announces positive FDA action on Aczone(TM) 2Health News:QLT announces positive FDA action on Aczone(TM) 3Health News:Superstar John McEnroe to Highlight The Kennedy Funding Invitational Tennis Tournament, July 9-13, 2008 2Health News:Superstar John McEnroe to Highlight The Kennedy Funding Invitational Tennis Tournament, July 9-13, 2008 3Health News:Superstar John McEnroe to Highlight The Kennedy Funding Invitational Tennis Tournament, July 9-13, 2008 4